Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

49.25 +0.33 (+0.67%)
Streaming Delayed Price Updated: 9:48 AM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen (URGN) Q2 2026 Earnings Call Transcript ↗
ZUSDURI revenue hit $50.4M, growing 73% QoQ as adoption expands into community practices. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Urogen Pharma Q2 Earnings Call Highlights ↗
Urogen Pharma (NASDAQ:URGN) reported second-quarter 2026 revenue of $72.5 million, up from $24.2 million a year earlier, as the commercial launch of bladder cancer treatment ZUSDURI continued to gain... 
Via MarketBeat
Topics Earnings
Urogen Pharma (NASDAQ:URGN) Nears 52-Week High on Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth ↗
Via Chartmill
UroGen Pharma (NASDAQ:URGN) Crushes Q1 Estimates as ZUSDURI Momentum Accelerates ↗
Via Chartmill
News headline image
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET 
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run ↗
Mark Schoenberg's final disposition under a pre-established Rule 10b5-1 plan follows 191% annual returns, leaving him with 119,763 shares worth $4.82 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? ↗
Focused on innovative cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? ↗
Focused on urinary tract cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation. 
Via The Motley Fool
News headline image
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen (URGN) Q1 2026 Earnings Transcript ↗
UroGen (URGN) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET 
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates. 
Via The Motley Fool
News headline image
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗
Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs. 
Via The Motley Fool
News headline image
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗
This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗
This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish ↗
This clinical-stage biotech develops therapies for CML, NASH, and obesity. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.